Does the media prefer ONC or PRAX?

In the previous week, BeOne Medicines had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 26 mentions for BeOne Medicines and 24 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.93 beat BeOne Medicines' score of 0.54 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 9 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor PRAX or ROIV?

In the previous week, Praxis Precision Medicines had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 24 mentions for Praxis Precision Medicines and 20 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.06 beat Praxis Precision Medicines' score of 0.93 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 9 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Roivant Sciences 12 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRAX or INSM?

In the previous week, Insmed had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 25 mentions for Insmed and 24 mentions for Praxis Precision Medicines. Insmed's average media sentiment score of 0.97 beat Praxis Precision Medicines' score of 0.93 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 9 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BNTX or PRAX?

In the previous week, BioNTech had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 26 mentions for BioNTech and 24 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.93 beat BioNTech's score of -0.25 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 9 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Praxis Precision Medicines (PRAX) Competitors

$360.76 -9.40 (-2.54%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$366.00 +5.24 (+1.45%)

As of 08/7/2026 07:59 PM Eastern

Compare

PRAX vs. ONC, TEVA, ROIV, INSM, and BNTX

Should you buy Praxis Precision Medicines stock or one of its competitors? MarketBeat compares Praxis Precision Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Praxis Precision Medicines include BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Roivant Sciences (ROIV), Insmed (INSM), and BioNTech (BNTX).

How does Praxis Precision Medicines compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Praxis Precision Medicines (NASDAQ:PRAX) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

BeOne Medicines has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.15	$286.93M	$4.47	77.91
Praxis Precision Medicines	$8.55M	1,176.37	-$303.27M	-$13.37	N/A

BeOne Medicines presently has a consensus price target of $400.00, suggesting a potential upside of 14.85%. Praxis Precision Medicines has a consensus price target of $573.05, suggesting a potential upside of 58.85%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00

In the previous week, BeOne Medicines had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 26 mentions for BeOne Medicines and 24 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.93 beat BeOne Medicines' score of 0.54 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	9 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market.

BeOne Medicines has a net margin of 10.70% compared to Praxis Precision Medicines' net margin of 0.00%. BeOne Medicines' return on equity of 14.23% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Praxis Precision Medicines	N/A	-38.66%	-36.41%

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

BeOne Medicines beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Praxis Precision Medicines (NASDAQ:PRAX) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Teva Pharmaceutical Industries presently has a consensus price target of $42.00, suggesting a potential upside of 18.98%. Praxis Precision Medicines has a consensus price target of $573.05, suggesting a potential upside of 58.85%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00

In the previous week, Praxis Precision Medicines had 11 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 24 mentions for Praxis Precision Medicines and 13 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.34 beat Praxis Precision Medicines' score of 0.93 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	11 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	9 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Praxis Precision Medicines' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Praxis Precision Medicines	N/A	-38.66%	-36.41%

Teva Pharmaceutical Industries has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.35	$1.41B	$0.60	58.83
Praxis Precision Medicines	$8.55M	1,176.37	-$303.27M	-$13.37	N/A

Summary

Praxis Precision Medicines beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Roivant Sciences?

Praxis Precision Medicines (NASDAQ:PRAX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Praxis Precision Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-38.66%	-36.41%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Praxis Precision Medicines presently has a consensus target price of $573.05, suggesting a potential upside of 58.85%. Roivant Sciences has a consensus target price of $34.77, suggesting a potential downside of 4.31%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Roivant Sciences has lower revenue, but higher earnings than Praxis Precision Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,176.37	-$303.27M	-$13.37	N/A
Roivant Sciences	$8.26M	3,164.44	-$299.77M	-$0.60	N/A

Praxis Precision Medicines has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, Praxis Precision Medicines had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 24 mentions for Praxis Precision Medicines and 20 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.06 beat Praxis Precision Medicines' score of 0.93 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	9 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Roivant Sciences	12 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Praxis Precision Medicines beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Insmed?

Praxis Precision Medicines (NASDAQ:PRAX) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Insmed had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 25 mentions for Insmed and 24 mentions for Praxis Precision Medicines. Insmed's average media sentiment score of 0.97 beat Praxis Precision Medicines' score of 0.93 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	9 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines currently has a consensus price target of $573.05, suggesting a potential upside of 58.85%. Insmed has a consensus price target of $205.26, suggesting a potential upside of 56.57%. Given Praxis Precision Medicines' higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Insmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

Praxis Precision Medicines has higher earnings, but lower revenue than Insmed. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,176.37	-$303.27M	-$13.37	N/A
Insmed	$606.42M	46.86	-$1.28B	-$5.75	N/A

Praxis Precision Medicines has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Praxis Precision Medicines' return on equity of -38.66% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-38.66%	-36.41%
Insmed	-76.94%	-122.43%	-43.65%

Summary

Praxis Precision Medicines beats Insmed on 11 of the 16 factors compared between the two stocks.

How does Praxis Precision Medicines compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Praxis Precision Medicines (NASDAQ:PRAX) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

BioNTech presently has a consensus price target of $127.81, indicating a potential upside of 36.45%. Praxis Precision Medicines has a consensus price target of $573.05, indicating a potential upside of 58.85%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00

Praxis Precision Medicines has lower revenue, but higher earnings than BioNTech. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A
Praxis Precision Medicines	$8.55M	1,176.37	-$303.27M	-$13.37	N/A

In the previous week, BioNTech had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 26 mentions for BioNTech and 24 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.93 beat BioNTech's score of -0.25 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	9 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

BioNTech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Praxis Precision Medicines has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Praxis Precision Medicines	N/A	-38.66%	-36.41%

Summary

Praxis Precision Medicines beats BioNTech on 10 of the 17 factors compared between the two stocks.

Get Praxis Precision Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRAX vs. The Competition

Export

Metric	Praxis Precision Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.06B	$3.69B	$7.03B	$13.02B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-27.90	9.02	271.36	25.17
Price / Sales	1,176.37	1,304.20	603.59	89.49
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	10.35	18.10	13.25	6.22
Net Income	-$303.27M	-$13.25M	$3.45B	$342.66M
7 Day Performance	17.19%	6.24%	4.67%	4.41%
1 Month Performance	8.30%	-3.50%	-1.28%	-1.10%
1 Year Performance	685.29%	61.28%	77.33%	23.99%

Praxis Precision Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRAX Praxis Precision Medicines	4.0284 of 5 stars	$360.76 -2.5%	$573.05 +58.8%	+685.3%	$10.06B	$8.55M	N/A	110	Trending News Earnings Report Analyst Forecast
ONC BeOne Medicines	4.0864 of 5 stars	$325.90 flat	$394.00 +20.9%	+20.9%	$35.76B	$5.74B	72.91	12,000	Trending News Earnings Report Analyst Forecast Insider Trade
TEVA Teva Pharmaceutical Industries	4.0938 of 5 stars	$31.08 +0.9%	$41.78 +34.4%	+116.0%	$35.43B	$17.26B	23.37	33,950
ROIV Roivant Sciences	1.6242 of 5 stars	$34.72 -0.8%	$33.59 -3.3%	+216.3%	$25.18B	$8.26M	N/A	860	Trending News Analyst Forecast
INSM Insmed	4.0087 of 5 stars	$104.73 -2.0%	$209.13 +99.7%	+19.7%	$23.18B	$606.42M	N/A	1,664	Trending News Earnings Report Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRAX) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. ONC, TEVA, ROIV, INSM, and BNTX

How does Praxis Precision Medicines compare to BeOne Medicines?

Summary

How does Praxis Precision Medicines compare to Teva Pharmaceutical Industries?

Summary

How does Praxis Precision Medicines compare to Roivant Sciences?

Summary

How does Praxis Precision Medicines compare to Insmed?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. ONC, TEVA, ROIV, INSM, and BNTX

How does Praxis Precision Medicines compare to BeOne Medicines?

Which has higher valuation and earnings, ONC or PRAX?

Do analysts rate ONC or PRAX?

Does the media prefer ONC or PRAX?

Which has more risk and volatility, ONC or PRAX?

Is ONC or PRAX more profitable?

Do institutionals & insiders have more ownership in ONC or PRAX?

Summary

How does Praxis Precision Medicines compare to Teva Pharmaceutical Industries?

Do analysts rate TEVA or PRAX?

Does the media favor TEVA or PRAX?

Which has more volatility & risk, TEVA or PRAX?

Do insiders and institutionals have more ownership in TEVA or PRAX?

Is TEVA or PRAX more profitable?

Which has better valuation & earnings, TEVA or PRAX?

Summary

How does Praxis Precision Medicines compare to Roivant Sciences?

Is PRAX or ROIV more profitable?

Do analysts recommend PRAX or ROIV?

Which has higher earnings and valuation, PRAX or ROIV?

Which has more risk and volatility, PRAX or ROIV?

Does the media favor PRAX or ROIV?

Do insiders & institutionals have more ownership in PRAX or ROIV?

Summary

How does Praxis Precision Medicines compare to Insmed?

Do institutionals and insiders hold more shares of PRAX or INSM?

Does the media favor PRAX or INSM?

Do analysts recommend PRAX or INSM?

Which has preferable valuation and earnings, PRAX or INSM?

Which has more risk & volatility, PRAX or INSM?

Is PRAX or INSM more profitable?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Do analysts rate BNTX or PRAX?

Which has higher valuation & earnings, BNTX or PRAX?

Does the media refer more to BNTX or PRAX?

Which has more risk & volatility, BNTX or PRAX?

Do institutionals & insiders believe in BNTX or PRAX?

Is BNTX or PRAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools